CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by $0.01, Bloomberg Earnings reports.

Shares of CASI Pharmaceuticals (NASDAQ:CASI) opened at 0.99 on Tuesday. The firm’s market capitalization is $59.59 million. CASI Pharmaceuticals has a 12-month low of $0.91 and a 12-month high of $1.76. The firm has a 50-day moving average of $1.05 and a 200 day moving average of $1.17.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at

Several research firms have weighed in on CASI. Maxim Group set a $4.00 target price on shares of CASI Pharmaceuticals and gave the stock a “buy” rating in a report on Monday. ValuEngine upgraded shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 13th.

A hedge fund recently raised its stake in CASI Pharmaceuticals stock. Renaissance Technologies LLC boosted its position in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 103.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,800 shares of the biotechnology company’s stock after buying an additional 63,500 shares during the period. Renaissance Technologies LLC owned about 0.21% of CASI Pharmaceuticals worth $144,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 3.90% of the company’s stock.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Earnings History for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.